Post-transplant lymphoproliferative disorder following renal transplantation: A single-center experience over 40 years: Original Article: Clinical Investigations

International Journal of Urology

Volumn 17, Issue 1, 2010, Pages 48-54

  Abe, Toyofumi ^a   Ichimaru, Naotsugu ^a   Kokado, Yukito ^b   Maeda, Tetsuo ^a   Kakuta, Yoichi ^a   Okumi, Masayoshi ^a   Imamura, Ryoichi ^a   Nonomura, Norio ^a   Isaka, Yoshitaka ^a   Takahara, Shiro ^a   Okuyama, Akihiko ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Takahashi Clinic   (Japan)

Author keywords

Malignant lymphoma; Post transplant lymphoproliferative disorder (PTLD); Renal transplantation; Rituximab

Indexed keywords

15 DEOXYSPERGUALIN; ASPARAGINASE; AZATHIOPRINE; BASILIXIMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; ETOPOSIDE; METHYLPREDNISOLONE; MITOXANTRONE; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; RITUXIMAB; SOBUZOXANE; TACROLIMUS; VINCRISTINE;

ADULT; ALLERGIC GLOMERULONEPHRITIS; ARTICLE; CHRONIC GLOMERULONEPHRITIS; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; TREATMENT DURATION;

ADULT; FEMALE; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; SURVIVAL RATE; TIME FACTORS;

EID: 74049102352     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2009.02405.x     Document Type: Article

References (17)

1. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf. 2000 23 : 101 113.
2. Holmes RD, Sokol RJ. Epstein-Barr virus and post-transplant lymphoproliferative disease. Pediatr. Transplant. 2002 6 : 456 464.
3. Wigle DA, Chaparro C, Humar A, Hutcheon MA, Chan CK, Keshavjee S. Epstein-Barr virus serology and posttransplant lymphoproliferative disease in lung transplantation. Transplantation 2001 72 : 1783 1786.
4. Walker RC, Marshall WF, Strickler JG et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin. Infect. Dis. 1995 20 : 1346 1353.
5. Dharnidharka VR, Araya CE. Post-transplant lymphoproliferative disease. Pediatr. Nephrol. 2009 24 : 731 736.
6. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. Br. Med. J. 2005 331 : 810.
7. Dotti G, Fiocchi R, Motta T et al. Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation 2000 69 : 827 833.
8. Leblond V, Davi F, Charlotte F et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J. Clin. Oncol. 1998 16 : 2052 2059.
9. Penn I. The role of immunosuppression in lymphoma formation. Springer Semin. Immunopathol. 1998 20 : 343 355.
10. Kogan DL, Burroughs M, Emre S et al. Prospective longitudinal analysis of quantitative Epstein-Barr virus polymerase chain reaction in pediatric liver transplant recipients. Transplantation 1999 67 : 1068 1070.
11. Pirsch J, Stratta R, Sollinger H et al. Treatment of severe Epstein-Barr virus-induced lymphoproliferative syndrome with ganciclovir. Am. J. Med. 1989 86 : 241 244.
12. O'Brien S, Bernert RA, Logan JL, Lien YH. Remission of posttransplant lymphoproliferative disorder after interferon alfa therapy. J. Am. Soc. Nephrol. 1997 8 : 1483 1489.
13. Magnone M, Holley JL, Shapiro R et al. Interferon-alpha-induced acute renal allograft rejection. Transplantation 1995 59 : 1068 1070.
14. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV.6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): prevention and treatment. Nephrol. Dial. Transplant. 2002 17 (Suppl 4 31 3, 35 6.
15. Choquet S, Oertel S, LeBlond V et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann. Hematol. 2007 86 : 599 607.
16. Verschuuren EA, Stevens SJ, van Imhoff GW et al. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Transplantation 2002 73 : 100 104.
17. Tsai DE, Douglas L, Andreadis C et al. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. Am. J. Transplant. 2008 8 : 1016 1024.